These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22825315)

  • 1. Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset.
    Ramos EM; Latourelle JC; Lee JH; Gillis T; Mysore JS; Squitieri F; Di Pardo A; Di Donato S; Hayden MR; Morrison PJ; Nance M; Ross CA; Margolis RL; Gomez-Tortosa E; Ayuso C; Suchowersky O; Trent RJ; McCusker E; Novelletto A; Frontali M; Jones R; Ashizawa T; Frank S; Saint-Hilaire MH; Hersch SM; Rosas HD; Lucente D; Harrison MB; Zanko A; Marder K; Gusella JF; Lee JM; Alonso I; Sequeiros J; Myers RH; Macdonald ME
    Hum Genet; 2012 Dec; 131(12):1833-40. PubMed ID: 22825315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier of Huntington disease age-at-onset in a large European cohort.
    Weydt P; Soyal SM; Landwehrmeyer GB; Patsch W;
    BMC Neurol; 2014 Jan; 14():1. PubMed ID: 24383721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset.
    Soyal SM; Felder TK; Auer S; Hahne P; Oberkofler H; Witting A; Paulmichl M; Landwehrmeyer GB; Weydt P; Patsch W;
    Hum Mol Genet; 2012 Aug; 21(15):3461-73. PubMed ID: 22589246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease.
    Taherzadeh-Fard E; Saft C; Akkad DA; Wieczorek S; Haghikia A; Chan A; Epplen JT; Arning L
    Mol Neurodegener; 2011 May; 6(1):32. PubMed ID: 21595933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16.
    Djoussé L; Knowlton B; Hayden MR; Almqvist EW; Brinkman RR; Ross CA; Margolis RL; Rosenblatt A; Durr A; Dode C; Morrison PJ; Novelletto A; Frontali M; Trent RJ; McCusker E; Gómez-Tortosa E; Mayo Cabrero D; Jones R; Zanko A; Nance M; Abramson RK; Suchowersky O; Paulsen JS; Harrison MB; Yang Q; Cupples LA; Mysore J; Gusella JF; MacDonald ME; Myers RH
    Neurogenetics; 2004 Jun; 5(2):109-14. PubMed ID: 15029481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex contribution to average age at onset of Huntington's disease depends on the number of (CAG)
    Stanisławska-Sachadyn A; Krzemiński M; Zielonka D; Krygier M; Ziętkiewicz E; Sławek J; Limon J;
    Sci Rep; 2024 Jul; 14(1):15729. PubMed ID: 38977715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the Influence of TBP CAG/CAA Repeats in Conjunction with HTT CAG Repeats on Huntington's Disease Age at Onset in a Brazilian Sample.
    da Silva IDS; Apolinário TA; de Andrade Agostinho L; Paiva CLA
    J Mol Neurosci; 2022 May; 72(5):1116-1124. PubMed ID: 35275350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds.
    Andresen JM; Gayán J; Cherny SS; Brocklebank D; Alkorta-Aranburu G; Addis EA; ; Cardon LR; Housman DE; Wexler NS
    J Med Genet; 2007 Jan; 44(1):44-50. PubMed ID: 17018562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PGC-1alpha, a new therapeutic target in Huntington's disease?
    McGill JK; Beal MF
    Cell; 2006 Nov; 127(3):465-8. PubMed ID: 17081970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.
    Weydt P; Pineda VV; Torrence AE; Libby RT; Satterfield TF; Lazarowski ER; Gilbert ML; Morton GJ; Bammler TK; Strand AD; Cui L; Beyer RP; Easley CN; Smith AC; Krainc D; Luquet S; Sweet IR; Schwartz MW; La Spada AR
    Cell Metab; 2006 Nov; 4(5):349-62. PubMed ID: 17055784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age at onset in Huntington's disease: replication study on the association of HAP1.
    Karadima G; Dimovasili C; Koutsis G; Vassilopoulos D; Panas M
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1027-8. PubMed ID: 22698993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of the impact of lifestyle on age at onset of Huntington disease.
    Trembath MK; Horton ZA; Tippett L; Hogg V; Collins VR; Churchyard A; Velakoulis D; Roxburgh R; Delatycki MB
    Mov Disord; 2010 Jul; 25(10):1444-50. PubMed ID: 20629137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of the association of genotype and phenotype features of the pathogenesis of Huntington's chorea].
    Hryshchenko NV; Kucherenko AM; Patskun EI; Livshyts' LA
    Tsitol Genet; 2009; 43(3):42-7. PubMed ID: 19938636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene.
    Valcárcel-Ocete L; Alkorta-Aranburu G; Iriondo M; Fullaondo A; García-Barcina M; Fernández-García JM; Lezcano-García E; Losada-Domingo JM; Ruiz-Ojeda J; Álvarez de Arcaya A; Pérez-Ramos JM; Roos RA; Nielsen JE; Saft C; ; Zubiaga AM; Aguirre A
    PLoS One; 2015; 10(7):e0131573. PubMed ID: 26148071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutathione S-Transferase Omega 1 variation does not influence age at onset of Huntington's disease.
    Arning L; Jagiello P; Wieczorek S; Saft C; Andrich J; Epplen JT
    BMC Med Genet; 2004 Mar; 5():7. PubMed ID: 15040808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease.
    Clark J; Reddy S; Zheng K; Betensky RA; Simon DK
    BMC Med Genet; 2011 May; 12():69. PubMed ID: 21595954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and genetic characteristics of late-onset Huntington's disease in a large European cohort.
    Petracca M; Di Tella S; Solito M; Zinzi P; Lo Monaco MR; Di Lazzaro G; Calabresi P; Silveri MC; Bentivoglio AR
    Eur J Neurol; 2022 Jul; 29(7):1940-1951. PubMed ID: 35357736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease.
    Djoussé L; Knowlton B; Hayden M; Almqvist EW; Brinkman R; Ross C; Margolis R; Rosenblatt A; Durr A; Dode C; Morrison PJ; Novelletto A; Frontali M; Trent RJ; McCusker E; Gómez-Tortosa E; Mayo D; Jones R; Zanko A; Nance M; Abramson R; Suchowersky O; Paulsen J; Harrison M; Yang Q; Cupples LA; Gusella JF; MacDonald ME; Myers RH
    Am J Med Genet A; 2003 Jun; 119A(3):279-82. PubMed ID: 12784292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease.
    Arning L; Monté D; Hansen W; Wieczorek S; Jagiello P; Akkad DA; Andrich J; Kraus PH; Saft C; Epplen JT
    J Mol Med (Berl); 2008 Apr; 86(4):485-90. PubMed ID: 18327563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.